ADaptiVe Biomarker Trial That InformS Evolution of Therapy
Phase of Trial: Phase I
Latest Information Update: 31 Dec 2018
At a glance
- Drugs BMS 986156 (Primary) ; Cabiralizumab (Primary) ; Ipilimumab (Primary) ; Linrodostat (Primary) ; Lirilumab (Primary) ; Nivolumab (Primary) ; Relatlimab (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Acronyms ADVISE
- Sponsors Bristol-Myers Squibb
- 19 Dec 2018 Planned End Date changed from 31 Jan 2022 to 16 Apr 2022.
- 19 Dec 2018 Planned primary completion date changed from 30 Jan 2020 to 15 Apr 2020.
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.